À titre de membre permanent, vous pourrez accéder au contenu éditorial et de formation continue, utiliser le moteur de recherche, recevoir nos newsletters, participer aux discussions, télécharger des diapositives et plus encore.
Adding valsartan to therapy in high-risk hypertensive patients reduced the risk of cardiovascular events more than conventional non-ARB treatment in both the primary- and secondary-prevention setting, according to an analysis from KYOTO HEART, while JIKEI HEART investigators suggest a benefit with valsartan in coronary artery disease patients.
Stockholm, Sweden - The addition of the angiotensin-receptor blocker (ARB) valsartan (Diovan, Novartis) to therapy in high-risk hypertensive patients reduced the risk of cardiovascular events more than conventional non-ARB treatment in both the primary- and secondary-prevention setting, according to the results of a new analysis.
The data, from an analysis of the KYOTO HEARTstudy, showed that valsartan reduced the risk of the primary end point, a composite of hard and soft cardiovascular end points, 56% in primary-prevention patients and 37% in secondary-prevention patients, when compared with non-ARB treatment. There was no significant difference in blood pressure in the two treatment arms, suggesting, like the overall trial, the benefit is not derived from any antihypertensive effects. Read full article »